Home » Portfolio » Imacure 100mg Tablet

Imacure 100

API

Imatinib Mesylate 100mg

Dosage Form

Tablets

Available Strength

Manufactured Facility

Imacure 100 Tablet is used to treat several types of cancers. It is most commonly prescribed to treat blood cancers (chronic myeloid leukemia and acute lymphocytic leukemia) and gastrointestinal stromal tumors. It works by targeting specific proteins that contribute to the growth and spread of cancer cells. Imacure 100 Tablet is also used for treatment of a skin tumor called dermatofibrosarcoma protuberans and a type of bone marrow condition called aggressive systemic mastocytosis. The medicine should be taken with food. Take it at the same time each day to get the most benefit. Continue taking it as long as your doctor advises for it. The duration of treatment varies according to your need and response to treatment. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to. The most common side effects of this medicine include edema, nausea, vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue, and abdominal pain. Let your doctor know if you experience unexpected rapid weight gain. Your doctor may advise for regular monitoring of blood cells and liver function while you are taking this medicine. Do not drive or do anything requiring mental focus if you experience dizziness and blurry vision. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.
  • First-Line treatment of CML CP Significantly Improved QOL
  • Overall est. survival rate* was 83.3% with Imatinib compared to 65.6% with interferon alfa plus cytarabine
  • Approx. 82.8% Patients completed cytogenetic response.
IndicationDosage
Philadelphia chromosome positive chronic myeloid leukaemia (Chronic phase)400 mg/day
Philadelphia chromosome positive chronic myeloid leukaemia ( Accelerated phase or Blast crisis)600 mg/day
Philadelphia chromosome positive chronic myeloid leukaemia (Paediatric)340 mg/m2/day
(not exceeding 800 mg/m2/day)
Philadelphia chromosome positive + Acute lymphoblastic leukaemia600 mg/day
Philadelphia chromosome positive + Acute lymphoblastic leukaemia (Paediatric)340 mg/m2 daily
not to exceed the total dose of 600 mg
Myelodysplastic/ Myeloproliferative disorders400 mg/day
Aggressive systemic mastocytosis100 to 400 mg/day (escalation)
Hypereosinophilic syndrome (HES) / Chronic eosinophilic leukaemia (CEL)100 to 400 mg/day (escalation)
Dermatofibrosarcoma protuberans800 mg/day
Metastatic and/or unresectable Gastrointestinal stromal tumours400 mg/day
Adjuvant treatment of Gastrointestinal stromal tumours400 mg/day